Dabrafenib, Trametinib Active in Pediatric Glioma With BRAF V600
More responses, longer progression-free survival seen compared with standard chemo for low-grade glioma with BRAF V600 mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.